Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. ASCO 2018. J Clin Oncol. 2018;36 (suppl; abstr 9503).
PARP-remmers: een nieuw tijdperk in de behandeling van (recidiverende) ovariumkanker
aug 2020 | Gynaecologische oncologie